A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Rochester, United States. In N Engl J Med, 03 Oct 2015
Treatment-related adverse events included grade 4 thrombocytopenia (in 18% of patients), grade 4 neutropenia (in 12%), grade 3 anemia (in 30%), and grade 1 or 2 elevation in levels of total bilirubin (in 12%), alkaline phosphatase (in 21%), and aspartate aminotransferase (in 27%).
Methotrexate for maintenance of remission in ulcerative colitis.
London, Canada. In Cochrane Database Syst Rev, Sep 2015
Adverse events reported in these studies included transient leucopenia, migraine, nausea and dyspepsia, mild alopecia, mild increase in aspartate aminotransferase levels, peritoneal abscess, hypoalbuminemia, severe rash and atypical pneumonia AUTHORS' CONCLUSIONS: The results for efficacy and safety outcomes between methotrexate and placebo, methotrexate and sulfasalazine, methotrexate and 6-mercaptopurine and methotrexate and 5-aminosalicylic acid were uncertain.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Boston, United States. In Lancet Oncol, Jul 2015
Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [<1%]), hyperbilirubinaemia (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]).
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shanghai, China. In Lancet Oncol, Jun 2015
The most frequent grade 3 or higher regorafenib-related adverse events were hand-foot skin reaction (22 [16%] of 136 patients in the regorafenib group vs none in the placebo group), hypertension (15 [11%] vs two [3%] of 68 patients in the placebo group), hyperbilirubinaemia (nine [7%] vs one [1%]), hypophosphataemia (nine [7%] vs none), alanine aminotransferase concentration increases (nine [7%] vs none), aspartate aminotransferase concentration increases (eight [6%] vs none), lipase concentration increases (six [4%] vs one [1%]), and maculopapular rash (six [4%] vs none).
Serum Gamma-Glutamyltransferase and Ferritin are Related to Insulin Resistance: A Population-Based Study.
In Clin Lab, Dec 2014
GGT was independently correlated with ferritin after adjustment for age, gender, place of residence, education, income, leisure-time physical activity, drinking, smoking, body mass index, systolic pressure, diastolic pressure, hepatitis B surface antigen, anti-hepatitis C virus, aspartate aminotransferase, alanine aminotransferase, total cholesterol, low density lipoprotein-cholesterol, triglyceride, high density lipoprotein-cholesterol, fasting plasma glucose, 2-hour postprandial plasma glucose, uric acid, and urinary albumin to creatinine ratio (p < 0.05).
Objective Diagnosis of Chronic Alcohol Abuse - Determination of Carbohydrate-Deficient Transferrin (CDT) with Capillary Electrophoresis.
Roma, Italy. In Forensic Sci Rev, 2000
The present paper reviews briefly in terms of diagnostic sensitivity and specificity the most important conventional markers of chronic alcohol abuse - e.g., γ-glutamyl transferase (GGT), erythrocyte mean corpuscular volume (MCV), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) - as well as those more recently proposed, namely aldehyde dehydrogenase (ALDH), high density lipoprotein cholesterol, serum triglycerides, urate, fatty acid ethyl and methyl esters, phosphatidylethanol, dolichols, β-hexosaminidase and protein acetaldehyde adducts.